Ribociclib Plus Hormone Therapy Safety and Adherence Study
Part of Cancer, Skin clinical trials.
This study tracks how well patients take ribociclib (a cancer-fighting drug) combined with hormone therapy for early-stage breast cancer, and monitors for any side effects. The goal is to understand real-world use and help patients stay on treatment safely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have early-stage breast cancer (HR+ and HER2-negative) and your doctor has prescribed ribociclib plus an aromatase inhibitor
- You have not yet started your first cycle of ribociclib treatment
- You are 18 years or older
- You live in Slovenia and have Slovenian health insurance
- You speak and understand Slovenian fluently
- You have access to a phone and can participate in follow-up calls
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding ribociclib (a targeted pill) to standard hormone therapy for people with early but high-risk HR-positive, HER2-negative breast cancer, after surgery.
This trial looks at how well ribociclib works and why it may stop working over time in people with advanced, hormone-receptor–positive, HER2-negative breast cancer. It also analyzes blood and tissue samples to help researchers understand resistance patterns and improve future treatment decisions.
This trial tests ribociclib, a targeted therapy, for women with hormone receptor-positive, HER2-negative breast cancer who still have cancer cells in the breast or lymph nodes after initial chemotherapy. It aims to reduce the chance of cancer coming back.
This study looks at how well ribociclib works when given with hormone therapy after surgery for certain types of breast cancer. It aims to understand real-world benefits and safety for patients in Russia.
This study compares how well breast cancer patients take their medication (ribociclib) with or without using a mobile app. It aims to see if the app helps patients stick to their treatment plan.
This trial tests a new combination of ribociclib and anastrozole as a first treatment for advanced hormone receptor-positive, HER2-negative breast cancer that has not been treated before. It may help if you have not received any prior therapy for metastatic disease.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.